Depomed — Proxy Contest (October 2015)
11 slides from Depomed's proxy contest presentation, Oct 13, 2015
Slide 1: Execution of Business Model Driving Triple Digit Growth in Sales and Significant Profitability
Depomed’s Execution of Business Model Driving Triple Digit Growth in Sales and Significant Profitability 7 $500K $27.1M $58.1M $114M $320M-340M (1) September 2015 2015 Total Product Sales Guidance (Includes NUCYNTA starting April 2, 2015) Adjusted EBITDA (Midpoint of adjusted EBITDA Guidance) $102.5
Slide 2: Depomed's Clear Track Record of Value Creation
Depomed’s Clear Track Record of Value Creation 9 September 2015 Depomed is in a Period of Significant Growth and is Well-Positioned for Future Success Source: Stock chart from BigCharts.com 1-Year 2-Year 3-Year 5-Year 75% 276% 409% 650% Total Shareholder Return to Date (1) Covering 8/31/10 to 8/31/1
Slide 3: NUCYNTA Leading The Latest Chapter of Depomed's Growth Story – Blockbuster Potential
NUCYNTA Leading The Latest Chapter of Depomed’s Growth Story – Blockbuster Potential (1) Adds significant revenue and earnings to an already strong business Only new chemical entity in CII space approved by FDA in last 30 years Competes in multi-billion dollar pain market Exclusivity expected for a
Slide 4: Depomed's NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales
Depomed’s NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales (1) 13 September 2015 Proper Dosing Pricing and Access Positioning Promotion Significantly increased promotion and marketing efforts Revamped product positioning and messaging Maximize brand through pricing and access strat
Slide 5: NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More
NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More (1) 20 September 2015 NUCYNTA >$500MM by 2020 and $1 Billion Before Patent Expiry (2) February 2023: Expiry of patents covering tapentadol (composition of matter plus pediatric extension) December 2025: Expiry of p
Slide 6: Depomed's Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA
21 September 2015 Depomed’s Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA Product Differentiation 2Q Annualized Revenues Growth Over 1Q 2015 Expected Exclusivity (1) 1x daily with less dizziness and somnolence $84M 21% April 2015 ANDA settlement provides exclusivity to 202
Slide 7: Depomed's Ability to Efficiently Execute and Deliver Growth - Gralise
23 September 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - Gralise Reacquired marketing rights March 2011 and received $40M payment Launched in October 2011 >$84 million run rate as of Q2 2015 Tier 2 coverage at the three largest pharmacy benefit managers, CVS/Caremark, ESI, Cat
Slide 8: Depomed's Ability to Efficiently Execute and Deliver Growth - CAMBIA
24 September 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - CAMBIA Acquired in December 2013 for $48.7M Relaunched in December 2013 $27 million run rate as of Q2 2015 Only single agent in its therapeutic class approved in the U.S. for treatment of acute migraine attacks in adults
Slide 9: Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth for a Long Time
Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth for a Long Time 26 September 2015 Securing Market Exclusivity for Depomed Products Well Into Next Decade (1) Product Expected Exclusivity 2028 Acquired April 2015; composition of matter patent to 2022/2023; polymorph and method
Slide 10: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth
29 September 2015 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Strong Product Portfolio Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity (1) Track Record of Accelerated Growth Organic growth - success increasing product sales
Slide 11: Forward-Looking Statements & Other Legal Information
Forward-Looking Statements & Other Legal Information The statements that are not historical facts contained in this filing are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to Depomed’s prospects as a standalone business, Depomed’s busin